Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
Steven M. Opal(Brown University), Daniel P. Rossignol(Memorial Hospital of Rhode Island), Marc Van Nuffelen(Memorial Hospital of Rhode Island), Jan Pachl(Charles University), Takeshi Takahashi(National Institute of Information and Communications Technology), Roland M.H. Schein, Melvyn Lynn(Memorial Hospital of Rhode Island), Luis Jáuregui(Memorial Hospital of Rhode Island), Thierry Dugernier(Clinique Saint Pierre), Sandra Oeyen(Ghent University Hospital), Naoki Aikawa(Keio University), D. Perrotin(Université de Tours), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), André C. Kalil(Nebraska Medical Center), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Steven P. LaRosa(Eli Lilly (United States)), Edward M. Cordasco(Memorial Hospital of Rhode Island), Jean‐Paul Mira(Hôpital Cochin), C. Peckelsen(Memorial Hospital of Rhode Island), Chia-Sheng Chang(China Medical University), Bruno François(Inserm), Kenneth Krell(Eastern Idaho Technical College), Derek C. Angus(MACOM (United States)), Tatsuya Maruyama(Keio University), Mark Tidswell(Tufts University)
Unknown
January 1, 2013
Cited by 7
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k